RxDoctor Payments Data

Svetlana Shimberg, NP

Nurse Practitioner · Chelmsford, MANPI 1982151080

Payments from drug & device makers

$3,058in general payments, 2019–2025

Across 136 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • AstraZeneca$416
  • Boehringer Ingelheim$229
  • Otsuka America Pharmaceutical, Inc.$214
  • Pfizer$206
  • Astellas Pharma US Inc$202
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,88494%
  • Education$1746%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,058 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$16,845
Medicare patients
103
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$68,812
JardianceEmpagliflozin89$55,955
CreonLipase/Protease/Amylase37$52,814
EliquisApixaban62$44,285
LinzessLinaclotide79$42,472
TradjentaLinagliptin48$25,636
FarxigaDapagliflozin Propanediol39$23,501
JanuviaSitagliptin Phosphate21$18,010
XareltoRivaroxaban21$11,801
JanumetSitagliptin Phos/Metformin Hcl17$10,558
VascepaIcosapent Ethyl26$7,454
Atrovent HfaIpratropium Bromide15$7,128
InvokanaCanagliflozin11$6,625
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$6,190
Incruse ElliptaUmeclidinium Bromide15$5,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$656$95,285116 claims
Boehringer IngelheimJardiance, Tradjenta$229$81,591137 claims
AmgenOtezla$55$68,81214 claims
PfizerEliquis$206$44,28562 claims
AstraZenecaFarxiga, Breztri Aerosphere$416$29,69152 claims
MerckJanuvia, Janumet$20$28,56838 claims
GSKIncruse Ellipta$25$5,81915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →